July 12th 2024
“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Nivolumab/Cabozantinib Combo Yielded Efficacy in Renal Cell Carcinoma Regardless of Nephrectomy
September 17th 2021Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.
Pembrolizumab Plus Lenvatinib Combo Approved for Treatment of First-Line Advanced RCC
August 12th 2021The combination of pembrolizumab plus lenvatinib received approval by the FDA in the first-line setting for patients with advanced renal cell carcinoma following the results of the phase 3 CLEAR trial.
FDA Grants Priority Review to BLA for Adjuvant Pembrolizumab in Certain Cases of RCC After Surgery
August 10th 2021A priority review to a biologics license application has been granted by the FDA for adjuvant pembrolizumab in certain populations of patients with renal cell carcinoma who have undergone surgery.
Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity, Maintains Safety in Metastatic RCC
July 28th 2021The combination of lenvatinib plus pembrolizumab showed antitumor activity and a manageable safety profile for treatment-naïve or previously treated patients with metastatic renal cell carcinoma.
Lenvatinib/Pembrolizumab Combo Improved Efficacy Over Sunitinib Across RCC Risk Groups
June 9th 2021Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.
HRQOL Analysis From CLEAR Trial Further Support Pembrolizumab/Lenvatinib Combo for Frontline RCC
June 7th 2021Across 3 health-related quality of life scales, the combination of pembrolizumab plus lenvatinib had similar or better outcomes than sunitinib for patients with metastatic renal cell carcinoma receiving treatment in the frontline.
Viktor Grünwald, MD, PhD, on CLEAR Trial Subgroup Analyses of Pembrolizumab/Lenvatinib in RCC
June 5th 2021CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.
Prolonged Duration of Response With Tivozanib for RCC Revealed at Long-Term Follow-Up
June 4th 2021Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.
Another installment of Clinical Quandaries is presented by Karen Férez-Blando, MD, and colleagues of a 45-year-old man with a diagnosis of intermediate-risk stage IV clear cell renal carcinoma who develops grade 2 hand-foot skin reaction on sunitinib therapy.